In the early 1990’s Dr. William Binder, the pioneer in the cosmetic therapeutic use of
BOTOX neurotoxin, made headlines by discovering that Botox was effective in relieving the pain and preventing the onset of migraine headaches. In 2000, Richard Glogau, MD, UCSF professor of dermatology, reported that 75 percent of patients in his case study experienced four to six months of Migraine relief following injections of Botox® to muscles of the face and head.
Glogau's small study of 24 patients adds weight to Dr. William Binder previous reports that
OnabotulinumtoxinA can relieve Migraines. “Chronic migraine is one of the most disabling forms of headache,” said Russel Katz, MD, director of Neurology Department for the FDA.
“Patients with chronic migraine experience a headache more than 14 days of the month. This condition can greatly affect family, work, and social life.” OnabotulinumtoxinA is a neurotoxin produced by Clostridium known to act at the neuromuscular junctions where it splits the synapstosome-associated protein 25kDa, leading to inhibition of acetylcholine release and muscle weakness.
The OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the
Double-Blind, Randomized,Placebo-Controlled Phases of the PREEMPT (Phase 3
REsearch Evaluating Migraine Prophylaxis Therapy) Clinical Program study was conducted by David W. Dodick, MD; Catherine C. Turkel, PharmD, PhD; Ronald E.
DeGryse, MS;Sheena K. Aurora, MD; Stephen D. Silberstein, MD; Richard B. Lipton, MD;
Hans-Christoph Diener, MD and Mitchell F. Brin, MD, on behalf of the PREEMPT Chronic
Migraine Study Group. The objective of the study was to assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX) as headache prophlaxis in adults with chronic migraine. Chronic migraine (CM) is a complex, progressive headache disorder affecting